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Introduction {#sec1}
============

Muscle wasting is prominent in many pathologies including metabolic disorders and neuromuscular diseases. Muscle wasting is also associated with aging and is highly prevalent in the elderly ([@bib7]). The molecular and cellular causes for aging-associated muscle wasting are diverse. Recently, we reported that muscle wasting is induced by reduced levels of poly(A)-binding protein nuclear 1 (PABPN1) ([@bib33]). PABPN1 levels are normally reduced in skeletal muscles during aging and are also associated with muscle weakness in oculopharyngeal muscular dystrophy (OPMD), a late-onset myopathy ([@bib1]). An expansion mutation in PABPN1 is the genetic cause for OPMD ([@bib8]). In OPMD, PABPN1 aggregates and hence depletes the levels of the functional protein ([@bib31]). PABPN1 regulates poly(A) tail length, alternative polyadenylation (APA) in the 3′ UTR or in internal regions, and nuclear export of transcripts, which together will affect mRNA expression levels, leading to an altered transcriptome ([@bib6]). The mechanisms by which PABPN1 depletion leads to muscle wasting are not fully understood.

Muscle wasting in OPMD mouse models is associated with the ubiquitin proteasome system (UPS) ([@bib2], [@bib3], [@bib41]). Also, in the mouse muscles with PABPN1 knockdown (shPab) muscle atrophy was found to be associated with altered mRNA levels of UPS genes that regulate muscle atrophy ([@bib33]). Reduced proteasomal activity in shPab muscles suggests that protein homeostasis is altered in shPab muscles. Protein homeostasis plays a central role in aging-associated muscle wasting ([@bib13]). Muscle contraction demands mitochondrial activity, and unsurprisingly altered mitochondrial activity was found in OPMD models, which was concomitant with shortened poly(A) tail length and APA in the 3′ UTR of mitochondrial genes ([@bib11], [@bib42]). Yet, how altered mRNA expression profiles lead to muscle wasting remains obscure.

Here we applied RNA sequencing (RNA-seq) and mass spectrometry in shPab muscles to identify the molecular and cellular causes for muscle wasting. We show that protein acetylation is reduced in shPab muscles and that deacetylation inhibition restores PABPN1-mediated muscle wasting.

Results {#sec2}
=======

PABPN1 Down-regulation Alters Muscle Histology {#sec2.1}
----------------------------------------------

We investigated the molecular mechanisms that are associated with PABPN1-driven muscle wasting in mouse tibialis anterior muscles expressing short hairpin RNA (shRNA) to *Pabpn1* (shPab). PABPN1 levels in muscles from four mice were compared between shPab and scrambled shRNA (scram) after contralateral injection, as previously described ([@bib33]). In this experimental setup analysis was paired, overcoming natural variations between mice. Muscles were harvested for *ex vivo* procedures including RNA-seq and mass spectrometry, and validations were carried out using qRT-PCR, western blot, and muscle histology ([Figure 1](#fig1){ref-type="fig"}A). Transduction efficiency was assessed by GFP fluorescence, which was included in the expression cassette. Overall, similar fluorescence was found in shPab and scram muscles ([Figure S1](#mmc1){ref-type="supplementary-material"}), indicating that any alterations in PABPN1 levels are not due to variation in transduction efficiency. Analysis of PABPN1 demonstrated reduced levels in shPab muscles ([Figures 1](#fig1){ref-type="fig"}B and 1C). Muscle histology was found to be altered between scram and shPab ([Figure 1](#fig1){ref-type="fig"}D). We confirmed thickening of the extracellular matrix (ECM) in shPab muscles ([Figure 1](#fig1){ref-type="fig"}D; [@bib33]). We also measured more myofibers per image frame in shPab compared with scram muscles ([Figure 1](#fig1){ref-type="fig"}E). Smaller myofibers could result from muscle atrophy, which is consistent with our previous study ([@bib33]); furthermore, it can concur with muscle regeneration. Central myonuclei and split myofibers were found in shPab muscles ([Figure 1](#fig1){ref-type="fig"}D). The fraction of central myonuclei in shPab was higher in three of the four mice ([Figure 1](#fig1){ref-type="fig"}F). PAX7 and *eMyh3* expression are molecular signatures of muscle regeneration ([@bib23], [@bib36], [@bib38]). qRT-PCR of *eMyh3* mRNA revealed higher levels in shPab muscles ([Figure 1](#fig1){ref-type="fig"}G). PAX7 staining also showed the same trend, wherein the fraction of PAX7-positive myonuclei was higher in shPab muscles ([Figures 1](#fig1){ref-type="fig"}H and 1I). Noticeably, the mouse with the highest PABPN1 fold change showed the most severe histological changes, whereas the mouse with the lowest fold change showed resilient changes.Figure 1Reduced PABPN1 Levels Induce Muscle Regeneration(A) Schematic workflow of the *ex vivo* analyses in scram and shPab muscles. RNA expression profiles (RNA-seq) are compared with the shPab proteome of the same muscles. The shPab acetylome was then analyzed. Procedures were validated using qRT-PCR, western blot (WB), or muscle histology. *Ex vivo* experiments were performed on paired muscles (N = 4 mice).(B) qRT-PCR of *Pabpn1* mRNA levels after normalization to Hprt housekeeping control. Paired dot plot is from N = 4 mice.(C) PABPN1 protein and levels in paired muscles. Representative western blot of PABPN1 and GAPDH loading control are shown. Paired dot plot shows PABPN1 levels after normalization to loading control, N = 4 mice.(D) Gomori trichrome tissue histology in cross sections. Images are of the mouse with highest PABPN1 fold change. White arrowheads point to ECM thickening, central myonuclei are depicted with red arrowheads, and split myofibers with black arrowheads. Scale bar, 50 μm.(E) Paired dot plot shows the mean number of myofibers per image frame, calculated from 5 frames per muscle (N = 8 muscles).(F) Paired dot plot shows the mean fraction of central nuclei in myofibers, calculated from 5 frames per muscle (N = 8 muscles).(G) Paired dot plot shows *eMyh3* mRNA levels in scram and shPab muscles (N = 4 mice). Expression values were calculated after normalization to *Hprt* and to the average *eMyh3* expression of all scram muscles.(H and I) (H) Representative fluorescent images for scram and shPab muscles stained with PAX7 antibody (green). Nuclei are counterstained with DAPI (blue). White arrowheads indicate nuclear PAX7. Scale bar, 7.5μm. (I) Paired dot plot shows the fraction of PAX7 positive nuclei in paired muscles. The percentage was calculated from over 1,000 nuclei per muscle (N = 6 muscles). In all dot plots paired muscles are connected with lines; blue or green lines mark the mouse with the highest or lowest PABPN1 fold change, respectively. Quantification of the muscle histology was performed over the entire muscle cross section. Means and standard deviations are depicted. Statistical difference was assessed with a paired test.

Proteomic Changes Surpass the Transcriptomic Changes in shPab Muscles {#sec2.2}
---------------------------------------------------------------------

The molecular mechanisms that are associated with PABPN1-mediated muscle pathology were investigated in the shPab transcriptome and proteome from the same muscles, using paired ratio t test. The shPab RNA expression profiles included 363 genes (5% false discovery rate \[FDR\]; [Figure 2](#fig2){ref-type="fig"}A, related to [Table S1](#mmc2){ref-type="supplementary-material"}), and those were predominantly enriched with genes of the ECM, mitochondria, and muscle-related genes (related to [Table S2](#mmc1){ref-type="supplementary-material"}). These expression profiles are consistent with OPMD expression profiles ([@bib2], [@bib32]). Moreover, higher expression of ECM genes is consistent with ECM thickening in shPab muscles ([@bib33]). qRT-PCR validation was carried out for *Pabpn1* and *eMyh3* ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}A). For the proteome, a 5% FDR cutoff was too strict (Related to [Table S3](#mmc3){ref-type="supplementary-material"}). Considering a p value cutoff of p \< 0.05, we identified differential expression of additional genes, such as *Rad32a* and *Map1lc3a*, which were previously reported as differentially expressed in shPab ([@bib30], [@bib33]). The shPab proteome contained 248 differentially expressed proteins (p \< 0.05) ([Figure 2](#fig2){ref-type="fig"}B, related to [Table S3](#mmc3){ref-type="supplementary-material"}). Western blot for seven proteins validated the proteomics results ([Figure S2](#mmc1){ref-type="supplementary-material"}). A significant correlation (p = 2.2 × 10^−16^) was found between mRNA and protein fold changes. The regression line is similar to the diagonal, although the correlation was small (R = 0.31) ([Figure 2](#fig2){ref-type="fig"}C). Overall, protein fold change was greater compared with mRNA fold change ([Figure S3](#mmc1){ref-type="supplementary-material"}). Focusing on the group of genes or proteins with higher fold changes (average fold change \> \|1.5\|) we found that the majority of the proteins had a positive fold change in shPab muscles (68%, [Figure 2](#fig2){ref-type="fig"}D). In contrast, a fold change direction preference was not found for the mRNAs ([Figure 2](#fig2){ref-type="fig"}D). The same fold change direction between mRNA and proteins was found for nearly 70% of the proteins, of which most proteins (74%) have higher levels in shPab ([Figure 2](#fig2){ref-type="fig"}E). In the group with opposite fold change direction between mRNA and protein (30%), the majority of proteins (80%) had higher levels in shPab ([Figure 2](#fig2){ref-type="fig"}E). Together, this suggests that in shPab muscles protein accumulation surpasses mRNA alterations. Moreover, protein accumulation in shPab suggests higher protein steady state, which is in agreement with reduced proteasome activity in shPab ([@bib33]).Figure 2Reduced PABPN1 Levels Result in a Greater Effect on Proteome Compared with Transcriptome(A) A volcano plot of the average mRNA fold change (FC) against p values in the shPab transcriptome. mRNAs that pass the cutoff p value \< 0.05 or p values corrected for false discovery rate are depicted in blue or red, respectively. Examples of validated genes are highlighted.(B) Volcano plot of the average protein fold change against p values in the shPab proteome. Proteins that pass the cutoff (p \< 0.05) are depicted in blue.(C) Scatterplot shows the fold changes between shPab proteome and transcriptome. Correlation (indicated as gray dashed line) was assessed with a Spearman rank test and compared with the diagonal (solid gray line). Average protein fold changes of 1.5 and −1.5 are indicated with red lines. Proteins with an average fold changes higher than 1.5 or lower than −1.5 are depicted in pink or black, respectively.(D) Bar chart shows fold change direction of shPab-affected genes (average fold change cutoff \> \|1.5\|) sorted for RNA or proteins.(E) Bar chart shows the percentage of proteins (average fold change cutoff \> \|1.5\|) with similar fold change direction or opposite fold change direction compared with RNA direction. Fold change higher than 1.5 is denoted in black and fold change lower than −1.5 in pink. Both transcriptome and proteome were determined from the same muscles (N = 4 mice).

A heatmap of the differential expressed proteins (p \< 0.05, N = 248 proteins) across the four individual mice revealed that the largest differences between scram and shPab muscles were found in the mouse with the highest PABPN1 fold change, whereas in the mouse with the lowest PABPN1 fold change the differences were the smallest ([Figure 3](#fig3){ref-type="fig"}A). This trend was then confirmed using k-means clustering. For 83 proteins, fold changes highly correlated with PABPN1 levels ([Figure S4](#mmc1){ref-type="supplementary-material"}). Validation using western blot was demonstrated for two proteins ([Figure S2](#mmc1){ref-type="supplementary-material"}). Together, these results suggest that the levels of a subset of proteins strongly correlate with the PABPN1 fold change.Figure 3PABPN1 Levels Affect Muscle Proteome of Which a Large Part Is Linked to Acetylation(A) Heatmap of protein abundance for the differentially expressed proteins (p \< 0.05). Muscles are paired; the mice with the highest and lowest PABPN1 fold change are depicted in blue and green, respectively. Western blot shows PABPN1 expression for each mouse. GAPDH was used as loading control. Mitochondrial proteins are highlighted with green lines, and ribosomal proteins are highlighted with red lines. Color key indicates the *Z* scores (based on rows).(B) Pie chart shows the significantly enriched protein groups (UP-keyword, David) of the differentially expressed proteins (p \< 0.05, n = 248). The transparent pies (outer circle) indicate the number of proteins within the protein groups that are linked to protein acetylation group. Numbers indicate the percentage per group.(C) The protein-protein interaction map shows protein networks for 248 proteins that pass the cutoff (p \< 0.05). Mitochondrial (green), translation (red), cytoskeletal (purple), and glycolysis (pink) clusters are highlighted. Within the mitochondrial cluster, the oxidative phosphorylation group is highlighted in dark green. Unconnected proteins are not shown, and networks with n \< 4 are removed. Proteins that are found in the acetylation group are highlighted in yellow, and those that were not found in the acetylation group are gray.

The cellular machineries that are affected by PABPN1 were then identified in the shPab proteome using enrichment analysis. The mitochondria, ribosome, cytoskeleton, nucleotide binding, glycolysis, and muscle proteins were found to be the most prominently affected ([Figure 3](#fig3){ref-type="fig"}B). Notably, mitochondrial proteins had lower levels, whereas most of the ribosomal proteins had higher levels in shPab muscles ([Figure 3](#fig3){ref-type="fig"}A). Next, protein-protein interaction networks of the differentially expressed proteins revealed that networks of the mitochondria, translation, cytoskeleton, and glycolysis were the most connected ([Figure 3](#fig3){ref-type="fig"}C). This suggests that the function of these cellular machineries is impaired in shPab muscles. Most striking, 63% of the proteins in the shPab proteome were enriched in the acetylation group (related to [Table S4](#mmc1){ref-type="supplementary-material"}). Most mitochondrial proteins in the shPab proteome were also found in the acetylation group ([Figures 3](#fig3){ref-type="fig"}B and 3C). Moreover, acetylation was also found to be abundant in the other enriched cellular machineries ([Figures 3](#fig3){ref-type="fig"}B and 3C), suggesting that acetylation might have a prominent role in shPab muscles.

shPab Muscles Are Characterized by Reduced Protein Acetylation {#sec2.3}
--------------------------------------------------------------

To elucidate the acetylated protein landscape in shPab muscles, a peptide pull-down with an antibody to acetylate lysine was carried out in scram and shPab muscles. For this purpose, protein extracts from seven mice, which were injected contralaterally with scram or shPab adeno-associated virus (AAV) 9 particles, were pooled and the pull-down peptides were identified using mass spectrometry ([Figure 4](#fig4){ref-type="fig"}A). In total, 2,229 peptides passed the 1% FDR and overlapped between two independent runs (related to [Table S5](#mmc4){ref-type="supplementary-material"}). A total of 1,830 peptides (82%) passed the coefficient of variation cutoff and were considered for subsequent analysis ([Figure 4](#fig4){ref-type="fig"}B). A confidence in the identified acetylated peptides was further assessed comparing our study in tibialis anterior muscles with the following published acetylome studies: in human and in rat skeletal muscles ([@bib24]) and in rat soleus ([@bib35]). Only ∼13% of the acetylated peptides overlapped between the human and rodent acetylomes (related to [Table S6](#mmc5){ref-type="supplementary-material"}A). As the human and rat studies came from the same laboratory and have a similar number of acetylated peptides ([@bib24]), it can be assumed that the limited overlap is not due to experimental settings or technical variations. The overlap between the two studies in rat was only 35% and comparable to the overlap between our study and the study in rat by Lundby et al. The specific muscle type was not specified in the study by Lundby et al. However, peptide overlap between fast-twitch tibialis anterior and slow-twitch soleus was only 13% (200 peptides; related to [Table S6](#mmc5){ref-type="supplementary-material"}B). In the pool of the overlapping peptides between soleus and tibialis anterior the mitochondria was highly enriched ([Table S6](#mmc5){ref-type="supplementary-material"}C), which is consistent with mitochondria enrichment in the acetylome studies in rat and humans ([@bib24]). Using western blot, we confirmed that the pattern of bulk protein acetylation highly differs between soleus and fast-twitch quadriceps in mouse ([Figure S5](#mmc1){ref-type="supplementary-material"}). Differences in histone acetylation were reported between fast and slow muscles ([@bib20]). Moreover, 82% of those overlapping acetylated proteins are also annotated in DAVID as acetylated proteins (related to [Table S6](#mmc5){ref-type="supplementary-material"}C). Together, this suggests that in skeletal muscles the acetylated mitochondrial proteins are highly abundant. Furthermore, it indicates that our acetylome study is suitable for further analysis.Figure 4The shPab-Dependent Acetylome(A) A workflow of the shPab acetylome procedure. Tibialis anterior muscles (N = 7 mice, contralateral injection of scram or shPab AAVs) were used. Protein extracts were pooled per genotype. Tryptic digestion, followed by immunoprecipitation with an anti-acetylated lysine (AcK) antibody, and mass spectrometry (MS) were carried out separately for the scram and shPab. Peptide analysis pipeline included an MS quality control (1% FDR) and coefficient of variation (CV) \< 0.3. The differentially acetylated peptides were considered with a 1.5-fold change (fold change) cutoff.(B) Scatterplot shows average peptide fold change (log2) versus average CV (-log2). Peptides with CV \< 0.3 and a fold change of \>1.5 and \< -1.5 are depicted with blue and red, respectively. Peptides that are only found in either shPab or scram muscle are lined as INF (infinite). Unchanged peptides are depicted in gray. The dashed line marks CV \< 0.3.(C and D) (C) Western blot of acetylated proteins in scram and shPab muscle protein extracts. GAPDH is loading control. (D) Immunofluorescence with AcK antibody in scram and shPab muscle cryosections. Left panels show an overlay between bright-field and DAPI staining of the nuclei (blue). The middle panels show AcK signal (yellow). Right panels show an enlarged AcK and DAPI overlay around the nuclei that are marked with an arrow. Intensity distribution plots for DAPI and AcK signal are made from the nucleus, which is marked with a line. Examples of AcK-positive and AcK-negative nuclei are in the upper and lower plots, respectively. Scale bar, 5 μm.(E) Bar chart shows the percentage of AcK-positive nuclei in scram and shPab muscles from four mice (unpaired). The number of measured nuclei is depicted within each bar. Trend for statistical difference was assessed with the Mann-Whitney test.(F) Fold change direction of nuclear proteins in the shPab acetylome: positive and negative fold changes are depicted in blue and red, respectively.(G) Pie chart shows the significantly affected gene ontology terms in the shPab acetylome.(H) Schematic representation of the acetylated and the shPab differentially acetylated oxidative phosphorylation subunits. The acetylated subunits in tibialis anterior muscle are highlighted in light green, and the shPab differentially acetylated are in dark green. The number of affected proteins in each complex is depicted.

We then investigated differential peptide acetylation between scram and shPab muscles and considered a fold change of 1.5 as a cutoff. In the shPab acetylome, 270 peptides were hypoacetylated and 137 peptides were hyperacetylated ([Figure 4](#fig4){ref-type="fig"}B). We found that 87 and 61 acetylated peptides were exclusively found in scram and shPab muscles, respectively ([Figure 4](#fig4){ref-type="fig"}B). This suggests an overall reduced acetylation in shPab muscles. Differences in protein acetylation between scram and shPab muscles were confirmed using western blot ([Figure 4](#fig4){ref-type="fig"}C). In addition, immunofluorescence also showed a decrease in the acetylation signal in shPab nuclei compared with scram muscles ([Figures 4](#fig4){ref-type="fig"}D and 4E). To confirm this observation, acetylation direction was assessed for nuclear proteins in the shPab acetylome. Hypoacetylation was also prominent in the nuclear proteins, including all histones ([Figure 4](#fig4){ref-type="fig"}F). Moreover, enrichment analysis of the differentially acetylated proteins (N = 171) showed that the mitochondria was highly enriched ([Figure 4](#fig4){ref-type="fig"}G). In addition, 42% of the differentially acetylated proteins were enriched in metabolic pathways ([Figure 4](#fig4){ref-type="fig"}G). The majority of the differentially acetylated oxidative phosphorylation proteins were found to be in complexes 1 and 5 ([Figure 4](#fig4){ref-type="fig"}H). These complexes catalyze, respectively, the production of NAD^+^ and ATP ([@bib22]). This could suggest aberrant mitochondrial activity in shPab muscles. In agreement, previously we reported reduced mitochondrial membrane potential in shPab muscle cell culture ([@bib1]). Acetylation of mitochondrial proteins is achieved by the NAD^+^-dependent deacetylases (sirtuins), among which SIRT1 is suggested to be central in aging-associated metabolic changes in muscles ([@bib10]).

PABPN1 Regulates SIRT1 mRNA Processing {#sec2.4}
--------------------------------------

We then examined SIRT1 levels in shPab muscles and found an elevated protein expression in shPab compared with scram muscles ([Figures 5](#fig5){ref-type="fig"}A and 5B). Interestingly, SIRT1 fold changes related to PABPN1 fold changes ([Figure 5](#fig5){ref-type="fig"}B). Therefore next we investigated whether SIRT1 is regulated by PABPN1 in an established PABPN1 knockdown muscle cell culture ([@bib15]). SIRT1 protein levels were also elevated in shPab cell culture ([Figure 5](#fig5){ref-type="fig"}C). Thus we examined whether *Sirt1* transcript level is directly regulated by PABPN1. APA was determined with the ratio between two primer sets to distal and proximal region in *Sirt1* 3′ UTR ([Figure 5](#fig5){ref-type="fig"}D). We found a lower distal to proximal ratio in shPab cell culture ([Figure 5](#fig5){ref-type="fig"}E), indicating APA utilization. APA often resulted in shorter transcripts that are more stable ([@bib15], [@bib19]). Using the proximal primer set we found higher *Sirt1* mRNA levels in shPab cell culture ([Figure 5](#fig5){ref-type="fig"}F). Consistently, also in the OPMD mouse model (A17.1) we found APA and higher levels in *Sirt1* mRNA ([Figure S6](#mmc1){ref-type="supplementary-material"}). Interestingly, APA and higher *Sirt1* expression were only found in fast-twitch quadriceps, but not in slow-twitch soleus ([Figure S6](#mmc1){ref-type="supplementary-material"}). In this mouse model, soleus is also less affected ([@bib41]).Figure 5*Sirt1* mRNA Levels Are PABPN1-Regulated via Alternative PAS in the 3′ UTR(A and B) SIRT1 levels in muscles of four mice. (A) A representative western blot in scram and shPab muscles. GAPDH is used as a loading control and for normalization. (B) Paired analysis of PABPN1 and SIRT1 fold change. Line connects values with a mouse. Mice with the smallest and highest PABPN1 fold changes are depicted with green and blue lines, respectively.(C) A representative western blot in muscle cell culture. GAPDH was used as loading control. GAPDH-normalized values are plotted in the bar chart.(D) A schematic presentation of alternative PAS utilization in the 3′ UTR in conditions with reduced PABPN1 levels. The positions of distal (D) and proximal (P) primer sets in *Sirt1* mRNA are depicted.(E and F) Distal to proximal ratio in *Sirt1* 3′ UTR (E) and *Sirt1* fold change (F) in scram or shPab muscle cell cultures. Fold change was calculated after normalization to *Hprt* housekeeping gene and scram control. Statistical difference was assessed with the Student\'s t test. p \< 0.05.(G) A schematic presentation showing the position of *Sirt1* AONs. AONs are designed to mask proximal PAS in *Sirt1* mRNA.(H and I) Bar charts show the distal to proximal ratio in *Sirt1* 3′ UTR (H) and the *Sirt1* fold change (I). Scrambled AON is depicted in the black bar, and with Sirt1 AONs are depicted in dashed bars. Fold change (I) was calculated after normalization to *Hprt* housekeeping gene and scram control. Averages and standard deviations of all the experiments here are from three biological replicates. Statistical difference was assessed with the Student\'s t test. p \< 0.05.

Next, we investigated whether *Sirt1* mRNA is directly regulated by APA utilization. We designed antisense oligonucleotides (AONs) specific to the proximal polyadenylation signal (PAS) in *Sirt1* 3′ UTR or scrambled AON ([Figure 5](#fig5){ref-type="fig"}G; Related to [Table S7](#mmc1){ref-type="supplementary-material"}). The AONs were transfected into cell cultures, and masking of proximal PAS was assessed using the distal to proximal ratio. Compared with scrambled AON, the distal to proximal ratio was higher in *Sirt1*-AONs in shPab cell culture ([Figure 5](#fig5){ref-type="fig"}H), and consistently, *Sirt1* long transcript levels were also elevated ([Figure 5](#fig5){ref-type="fig"}I). Together this suggests that in conditions with reduced PABPN1 levels *Sirt1* levels are modulated via APA utilization. In control cells, *Sirt1* mRNA was also elevated after *Sirt1*-AON transfection, which was not due to APA utilization ([Figures 5](#fig5){ref-type="fig"}H and 5I), suggesting that additional factors affect the stability of long *Sirt1* transcript.

SIRT1 Inhibition Elevates PABPN1 Expression in shPab Cell Culture {#sec2.5}
-----------------------------------------------------------------

Next, we investigated whether SIRT1 inhibition could reverse mitochondrial activity in shPab cell culture. Treatment with sirtinol, a SIRT1 inhibitor ([@bib43]), caused an increase in mitochondrial membrane potential in shPab cell culture ([Figure 6](#fig6){ref-type="fig"}A). Also, in shPab cell cultures that were treated with *Sirt1*-AON we found an increase in mitochondrial membrane potential ([Figure S7](#mmc1){ref-type="supplementary-material"}). In addition, sirtinol treatment restored muscle cell fusion in shPab cell culture ([Figure 6](#fig6){ref-type="fig"}B). Consistently, increased cell fusion was also found in stable SIRT1 knockdown cell culture ([Figure S8](#mmc1){ref-type="supplementary-material"}). This suggests that inhibition of SIRT1 activity restores PABPN1-mediated myogenic defects.Figure 6Sirtinol Treatment Reverses Myogenic Defects in shPab Muscle Cell Culture(A) Mitochondrial membrane potential in shPab vehicle and sirtinol-treated muscle cell cultures. Images show an overlay between monomers (green) and J-aggregates (red) and the nuclei (blue). Scale bar, 10 μm. The ratio is measured from \>30,000 cells.(B) Muscle cell fusion in shPab vehicle and sirtinol-treated cell cultures. Images show an overlay between MyHC staining (green) and the nuclei (blue). Scale bar, 20 μm. The fraction of nuclei within MyHC regions is from \>50,000 nuclei.(C) Western blot analysis of PABPN1 levels in sirtinol-treated scram and shPab cell cultures. Tubulin is used as loading control and for normalization.(D) Accumulation of nuclear PABPN1. Images show an overlay between PABPN1 (red) and nuclei (blue) in shPab vehicle and sirtinol-treated cell cultures. The segmented nuclei are depicted with a blue line. Scale bar, 10 μm. Bar chart shows the average MFI of nuclear PABPN1 from \>50,000 nuclei.(E and F) Distal to proximal ratio in *Sirt1* 3′ UTR (E) or mRNA fold change (F) in mock and sirtinol-treated shPab cell cultures. Fold change was calculated after normalization to *Hprt* and scram mock. Averages and standard deviations are from three biological replicates (A, B, D, E, F, and C, respectively). Statistical difference was assessed with the Student\'s t test. \*p \< 0.05.

We then explored if SIRT1 inhibition affects PABPN1 function. We found that PABPN1 protein levels were elevated in a dose-dependent manner with 10 μM as the optimal sirtinol concentration ([Figure S9](#mmc1){ref-type="supplementary-material"}). Consistently, PABPN1 increased in scram and shPab cells treated with sirtinol ([Figure 6](#fig6){ref-type="fig"}C). Consistently, PABPN1 levels were also increased in SIRT1 knockdown muscle cell culture ([Figure S8](#mmc1){ref-type="supplementary-material"}). Sirtinol treatment also elevated the levels of nuclear PABPN1 in shPab cell culture ([Figure 6](#fig6){ref-type="fig"}D). As nuclear PAPBN1 regulates APA utilization, we determined the distal to proximal ratio of *Sirt1* mRNA in sirtinol-treated cells, and found a reversion compared with shPab cell culture ([Figure 6](#fig6){ref-type="fig"}E). Consistently, *Sirt1* fold change was also reduced ([Figure 6](#fig6){ref-type="fig"}F). In a recent study we showed that PABPN1 also regulates levels of several autophagy-related genes ([@bib30]). Sirtinol treatment also restored levels of four of five autophagy-related genes ([Figure 6](#fig6){ref-type="fig"}F). Together, the results suggest that sirtinol treatment restores PABPN1 levels and its activity. Hence, this treatment could be beneficial in conditions with reduced PABPN1 levels.

Sirtinol Treatment Restores PABPN1-Mediated Muscle Wasting {#sec2.6}
----------------------------------------------------------

We then investigated the effect of sirtinol treatment in shPab muscles. Sirtinol or empty vehicle was contralaterally injected into shPab muscles of three mice ([Figure 7](#fig7){ref-type="fig"}A). Treatment was repeated twice, and muscles were harvested for *ex vivo* analyses ([Figure 7](#fig7){ref-type="fig"}A). Same as in cell culture, PABPN1 protein levels were increased in sirtinol-treated muscles ([Figures 7](#fig7){ref-type="fig"}B and 7C). In the sirtinol-treated shPab muscles ECM thickening was reduced and split myofibers were absent ([Figure 7](#fig7){ref-type="fig"}D). In addition, we observed a strong trend wherein the percentage of central nuclei decreased in sirtinol-treated muscles and myofiber cross-sectional area increased ([Figures 7](#fig7){ref-type="fig"}E and 7F). Previously we reported a shift in myofiber typing in shPab muscles: myosin-heavy chain (MyHC)-2b reduced, but MyHC-2a slightly increased ([@bib33]). Sirtinol treatment restored myofiber typing: MyHC-2b was elevated and MyHC-2a was reduced ([Figure 7](#fig7){ref-type="fig"}G). Last, we also noticed that MyHC-2b foci were formed in shPab muscles, which were completely absent in scram muscles ([Figure S10](#mmc1){ref-type="supplementary-material"}). This was consistent with our previous study ([@bib33]). MyHC-2b foci are formed by the loss of *ACTN3* ([@bib25]). In agreement, reduced ACTN3 protein levels were found in the shPab proteome (related to [Table S3](#mmc3){ref-type="supplementary-material"}). The number and size of MyHC-2b foci were decreased in sirtinol-treated shPab muscles ([Figure 7](#fig7){ref-type="fig"}H). Taken together, this suggests that sirtinol treatment could be beneficial in PABPN1-mediated muscle wasting.Figure 7Sirtinol Treatment in shPab Muscles Reverses PABPN1-Induced Muscle Pathology(A) An overview of sirtinol treatment in shPab muscles. Muscles were injected with AAV9 shPab in both right and left tibialis anterior muscles in three mice. After 3 weeks muscles were injected twice, with a 10-day interval, with empty vehicle or sirtinol.(B) A representative western blot shows PABPN1 protein levels in shPab vehicle and sirtinol-injected muscles. Equal loading is assessed with Coomassie blue (CB). The mouse with the lowest PABPN1 fold change is depicted with a light gray line.(C) Dot plot shows normalized PABPN1 expression levels. Lines connect paired muscles. Means and standard deviations are depicted with a black line.(D) Gomori trichrome staining in muscle cryosections. Extracellular thickening is depicted with a white arrow, examples of central myonuclei and split myofibers are indicated with red and black arrows, respectively. Scale bar, 20 μm.(E) Dot plot shows the fraction of central nuclei in mock and sirtinol-treated shPab muscles; \>1,500 myofibers were counted per condition per mouse. Lines connect between paired muscles. Control AAV9 scrambled shRNA was injected into tibialis anterior TA (N = 4 muscles). Means and standard deviations are depicted with a black line.(F) Cumulative distribution plot of myofiber cross-sectional area (CSA) in vehicle and sirtinol-treated muscles.(G) Myofiber typing: Images show an overlay of MyHC-2b (green), MyHC-2a (red), and DAPI (blue) staining in vehicle or sirtinol-treated shPab muscles. Scale bar, 20 μm. Cumulative distribution plot of MyHC-2a and MyHC-2b MFI in single myofibers from mock or sirtinol-treated muscles. Statistical difference was determined with the Kolmogorov-Smirnov test; \*p \< 0.0005.(H) Representative images of MyHC-2b foci in vehicle and sirtinol-treated shPab muscles. Scale bar, 50 μm. The upper right box shows segmented MyHC-2b foci. Chart bars show mean MyHC-2b foci per myofiber (left panel) and mean foci area (right panel). Statistical difference was assessed with the Student\'s t test. (F--H) Pooled myofibers from all muscles, number of single myofibers \> 1,000.

Discussion {#sec3}
==========

Muscle wasting is characterized by multiple histological alterations such as, atrophy, regeneration, thickening of the ECM, and switches in myofiber typing. Dysregulation of pathways regulating protein homeostasis, like the UPS and autophagy, play a role in muscle atrophy ([@bib37]). Reduced PABPN1 levels regulate expression levels of UPS, autophagy, and mitochondrial genes via APA utilization in the 3′ UTR, which consequently lead to reduced activity of all the cellular machineries ([@bib11], [@bib30], [@bib33]). Reduced PABPN1 levels cause myogenic defects in muscle cell culture ([@bib1], [@bib4]). Moreover, muscle wasting is found in mouse models for OPMD ([@bib41], [@bib42]). ECM thickening and central nuclei were also reported in affected OPMD muscles ([@bib32]). Also, in shPab muscles we found ECM thickening and central nuclei, suggesting that reduced PABPN1 levels cause multiple pathological features of muscle wasting and myogenic defects.

PABPN1 regulates mRNA processing, yet it is not fully understood how an altered transcriptome leads to muscle wasting pathology. Recently we showed that transcripts from APA in the 3′ UTR are under-represented in the translation machinery ([@bib30]). Substantial discrepancies between mRNA fold changes and translation efficiency were also reported in muscle cell cultures ([@bib14]). Here we found only limited correlation between transcript and protein fold changes in the same muscles. In agreement, limited overlap between transcriptome and proteome was also reported in muscles from aged adults ([@bib34]). Limited correlation between outcomes from RNA-seq-based transcriptome and mass-spectrometry-based proteome could be affected by technical issues and in-depth differences. Noteworthy is that for the more affected genes (fold change \|\>1.5\|), variation of their corresponding proteins is generally of a greater magnitude. This suggests that despite a genome-wide effect of PABPN1 on mRNA processing, only a subset of transcripts affect the muscle pathology. Higher protein fold changes in shPab muscles are consistent with lower proteasome activity and reduced autophagosome formation ([@bib30], [@bib33]). Posttranscriptional drivers of muscle wasting are associated with protein breakdown regulated by the ubiquitin proteasome and autophagy lysosome pathways ([@bib37]). Also, in aging muscles and in OPMD models, dysregulation of protein homeostasis seems to play a central role ([@bib3], [@bib27], [@bib32], [@bib42]). A broader effect on protein catabolism is implicated by higher levels of the ribosomal proteins in aging muscles, shPab muscles, and OPMD models ([@bib27], [@bib34], [@bib42]). In addition, reduced expression of mitochondrial proteins is also commonly found in shPab, OPMD, and aged muscles ([@bib27], [@bib34], [@bib42]). In OPMD muscles, reduced mitochondrial activity is correlated with APA utilization in a subset of mitochondrial genes ([@bib11]). Mitochondrial activity is more robustly regulated by reversible acetylation ([@bib5]). Acetylation of mitochondrial proteins is common in skeletal muscles ([@bib24]). Differential acetylation of mitochondrial proteins was found to be prominent in atrophic rat muscles ([@bib35]), and consistently also in shPab muscles, with complexes I and V being the most affected. NAD^+^ production is carried out in complex I, and sirtuins activity is NAD^+^ dependent. We show that deacetylation inhibition by sirtinol treatment in shPab restored mitochondrial membrane potential and myogenic defects.

Acetylation affects protein levels and function, among which the effect on metabolic processes is widely studied ([@bib16]). Acetylation is regulated by the sirtuins NAD^+^-dependent deacetylase gene family ([@bib18]). SIRT1 facilitates metabolic benefits in various cells across different tissues, and a central role in aging muscles was elucidated in many studies ([@bib10]). The mechanisms regulating SIRT1 levels in aging tissues are inadequately understood. Here we show that SIRT1 levels are directly tuned by PABPN1 via APA in the 3′ UTR. Masking the proximal polyadenylation site using specific AONs restored APA in SIRT1 and mitochondrial membrane potential in shPab muscle cell culture. Masking APA using oligonucleotides to pathogenic molecules was suggested as a specific silencing approach ([@bib12], [@bib26], [@bib29]). Moreover, SIRT1 inhibition restored PABPN1 levels, PABPN1 function, and myogenesis defects, suggesting that SIRT1, directly or indirectly, regulates PABPN1 levels. Acetylated PABPN1 was identified in the SIRT1-dependent acetylome ([@bib39]), suggesting that PABPN1 could be modulated by SIRT1-dependent deacetylation. Yet, how acetylation of PABPN1 affects its level and function should be explored in future studies. Nevertheless, we show that acetylation inhibition restored muscle wasting in shPab. Our results are consistent with studies suggesting that restoring NAD^+^ levels or targeting SIRT1 could ameliorate the age-associated disorders ([@bib17], [@bib43]) ([@bib40]). Moreover, sirtinol has been shown to reduce aggregation of the expanded PABPN1 in a *C. elegans* model for OPMD ([@bib9], [@bib28]). In prokaryotes, increased acetylation leads to enhanced aggregation and formation of inclusion bodies ([@bib21]). Whether deacetylation directly affects protein aggregation in muscles needs to be investigated in future studies.

Taken together, we show that muscle wasting, atrophy, and regeneration are induced by reduced PABPN1 levels. The shPab proteome shows a modulated protein acetylation profile, and the shPab acetylome is predominantly hypoacetylated. Reduced protein acetylation is consistent with higher SIRT1 levels. We show that *Sirt1* mRNA is regulated by PABPN1, and in turn, SIRT1 inhibition or knockdown elevates PABPN1 protein levels and restores PABPN1 molecular function. Consequently, cellular defects and muscle wasting are repaired in conditions with reduced PABPN1 levels. Our study suggests that maintaining physiological levels of both PABPN1 and SIRT1 is beneficial for muscles, and disturbance causes muscle wasting. This is the first study showing that reduced PABPN1 levels broadly affect protein acetylation. Future studies in other models and possibly in human aging muscles will further validate the role of PABPN1 in the protein acetylation landscape and its effect on muscle wasting.

Limitations of the Study {#sec3.1}
------------------------

This study presents the role of protein deacetylation in a mouse model, which was generated by AAV9-expressing shRNA to PABPN1. Our study design allowed paired analysis, excluding inter-mice variations. Yet, parts of this study should be replicated in other models. Recently, two other mouse models for PABPN1 were published ([@bib42]), and these should be considered in future studies. The role of protein deacetylation in aging muscles should be further studied in human muscles.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods, Figures S1--S10, and Tables S2, S4, S7--S10Table S1. The shPab Transcriptome, Related to Figure 2ATable S3. The shPab Proteome, Related to Figures 2B and CTable S5. The shPab Acetylome, Related to Figure 4BTable S6. A Comparison of Acetylome Studies in Skeletal Muscles, Related to Figure 4B

We thank Dr. Roman Fischer and Simon Davis from the Discovery Proteomics Facility within the TDI Mass Spectrometry Laboratory for their expert help and advice with the proteomics analysis. This study is supported by the AFM-Telethon \# 21160 to V.R. and by the Prinses Beatrix Spierfonds to V.R. and C.S.O. The B.M.K. lab was supported by the Engineering and Physical Sciences Research Council, United Kingdom (EP/N034295/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions {#sec5}
====================

The mouse model was generated by M.R. RNA-seq analysis was carried out by S.M.K. and V.R. Mass spectrometry and proteome study were carried out by C.S.O., R.K., P.D.C., A.P.-F. and B.M.K. Cell culture studies were carried out by C.S.O. and V.R. AONs were designed by A.A.-R. V.R. designed the study and made funding available. The manuscript was written by C.S.O. and V.R, and all authors commented on the manuscript.

Declaration of Interests {#sec6}
========================

All authors declare no conflict of interest.

Supplemental Information includes Transparent Methods, 13 figures, and 10 tables and can be found with this article online at [https://doi.org/10.1016/j.isci.2019.01.024](10.1016/j.isci.2019.01.024){#intref0010}.

A video abstract is available at [https://doi.org/10.1016/j.isci.2019.01.024\#mmc6](10.1016/j.isci.2019.01.024#mmc6){#intref0015}.

[^1]: These authors contributed equally

[^2]: Lead Contact
